Alzheimer’s Drug Discovery Foundation: Research Grants

Drug Development RFP

The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. This funding opportunity concentrates on diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia.

Funding: Up to $5,000,000 based on stage and scope of research. No overhead.
Neuroimaging and CSF Biomarker RFP

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

• Developing novel PET ligands for clinical trials
• Supporting novel CSF biomarkers
• Validating innovative MRI approaches in larger cohorts
• Developing novel measures of functional activity such as EEG

Funding: Up to $600,000 based on stage and scope of research. No overhead.

Prevention RFP
to support precision prevention studies, combination therapy studies, and comparative effectiveness research that probe whether the use or choice of interventions may reduce the risk of Alzheimer’s disease or other dementias. Studies that are not in humans will not be considered.
Funding: up to $5,000,000 for clinical trials based on stage and scope of research. No overhead.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities